皮下卡西瑞单抗与伊德单抗抗体联合治疗对比安慰剂对早期无症状SARS-CoV-2感染者发展为有症状COVID-19的影响:一项随机临床试验
这项随机、双盲、安慰剂对照的3期试验在美国、罗马尼亚和摩尔多瓦的112个中心纳入314例SARS-CoV-2 RT-qPCR阳性的无症状个体,按1:1随机接受单次皮下卡西瑞单抗与伊德单抗1200 mg(各600 mg)或安慰剂。在204例基线无症状且血清阴性的参与者中,抗体联合治疗组有症状COVID-19发生率显著低于安慰剂组(29.0% vs 42.3%),并减少了有症状周数和高病毒载量周数。
要点
- 皮下卡西瑞单抗与伊德单抗1200 mg可显著降低无症状SARS-CoV-2感染者28天内有症状COVID-19的发生率。
- 抗体联合治疗组有症状周数(每1000人895.7周 vs 1637.4周)和高病毒载量周数(每1000人489.8周 vs 811.9周)均低于安慰剂组。
- 抗体联合治疗组治疗中出现不良事件比例为33.5%,安慰剂组为48.1%。
核心结论
- 在无症状且SARS-CoV-2 RT-qPCR阳性、与感染家庭成员共同居住的个体中,与安慰剂相比,皮下卡西瑞单抗与伊德单抗抗体联合治疗显著降低了28天内有症状COVID-19的发生率。
研究设计与样本
- 随机、双盲、安慰剂对照的3期试验,在美国、罗马尼亚和摩尔多瓦的112个中心进行,纳入SARS-CoV-2感染指示病例的密切家庭接触者。
- 2020年7月13日至2021年1月28日入组,随访于2021年3月11日结束;年龄≥12岁的无症状个体在指示病例阳性检测样本采集后96小时内被识别方可入选。
- 报告314例SARS-CoV-2逆转录酶定量聚合酶链反应(RT-qPCR)检测阳性个体的结果,按1:1随机接受单次皮下卡西瑞单抗与伊德单抗1200 mg(各600 mg;n=158)或安慰剂(n=156)。
主要发现
- 314例随机参与者平均年龄41.0岁,51.6%为女性;310例(99.7%)完成疗效评估期;204例基线无症状且血清阴性者纳入主要疗效分析。
- 皮下卡西瑞单抗与伊德单抗1200 mg显著预防进展为有症状疾病:29/100(29.0%)vs 安慰剂44/104(42.3%);比值比0.54(95%CI,0.30-0.97);P=0.04;绝对风险差-13.3%(95%CI,-26.3%至-0.3%)。
- 卡西瑞单抗与伊德单抗减少了每1000名参与者的有症状周数(895.7周 vs 安慰剂1637.4周;P=0.03),相当于每例有症状参与者症状持续时间约减少5.6天。
- 卡西瑞单抗与伊德单抗还减少了每1000名参与者的高病毒载量周数(489.8周 vs 安慰剂811.9周;P=0.001)。
- 接受卡西瑞单抗与伊德单抗的参与者发生1次及以上治疗中出现不良事件的比例为33.5%,安慰剂组为48.1%,包括与COVID-19相关(25.8% vs 39.7%)或不相关(11.0% vs 16.0%)的事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Easy-to-administer anti-SARS-CoV-2 treatments may be used to prevent progression from asymptomatic infection to symptomatic disease and to reduce viral carriage. OBJECTIVE: To evaluate the effect of combination subcutaneous casirivimab and imdevimab on progression from early asymptomatic SARS-CoV-2 infection to symptomatic COVID-19. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, placebo-controlled, phase 3 trial of close household contacts of a SARS-CoV-2-infected index case at 112 sites in the US, Romania, and Moldova enrolled July 13, 2020-January 28, 2021; follow-up ended March 11, 2021. Asymptomatic individuals (aged ≥12 years) were eligible if identified within 96 hours of index case positive test collection. Results from 314 individuals positive on SARS-CoV-2 reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) testing are reported. INTERVENTIONS: Individuals were randomized 1:1 to receive 1 dose of subcutaneous casirivimab and imdevimab, 1200 mg (600 mg of each; n = 158), or placebo (n = 156). MAIN OUTCOMES AND MEASURES: The primary end point was the proportion of seronegative participants who developed symptomatic COVID-19 during the 28-day efficacy assessment period. The key secondary efficacy end points were the number of weeks of symptomatic SARS-CoV-2 infection and the number of weeks of high viral load (>4 log10 copies/mL). RESULTS: Among 314 randomized participants (mean age, 41.0 years; 51.6% women), 310 (99.7%) completed the efficacy assessment period; 204 were asymptomatic and seronegative at baseline and included in the primary efficacy analysis. Subcutaneous casirivimab and imdevimab, 1200 mg, significantly prevented progression to symptomatic disease (29/100 [29.0%] vs 44/104 [42.3%] with placebo; odds ratio, 0.54 [95% CI, 0.30-0.97]; P = .04; absolute risk difference, -13.3% [95% CI, -26.3% to -0.3%]). Casirivimab and imdevimab reduced the number of symptomatic weeks per 1000 participants (895.7 weeks vs 1637.4 weeks with placebo; P = .03), an approximately 5.6-day reduction in symptom duration per symptomatic participant. Treatment with casirivimab and imdevimab also reduced the number of high viral load weeks per 1000 participants (489.8 weeks vs 811.9 weeks with placebo; P = .001). The proportion of participants receiving casirivimab and imdevimab who had 1 or more treatment-emergent adverse event was 33.5% vs 48.1% for placebo, including events related (25.8% vs 39.7%) or not related (11.0% vs 16.0%) to COVID-19. CONCLUSIONS AND RELEVANCE: Among asymptomatic SARS-CoV-2 RT-qPCR-positive individuals living with an infected household contact, treatment with subcutaneous casirivimab and imdevimab antibody combination vs placebo significantly reduced the incidence of symptomatic COVID-19 over 28 days. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04452318.
引用
- O'Brien MP, Forleo-Neto E, Sarkar N, et al. Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial. JAMA. 2022. PMID: 35029629. doi:10.1001/jama.2021.24939
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。